메뉴 건너뛰기




Volumn 22, Issue 14, 2012, Pages 4731-4734

6β-N-Heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists

Author keywords

Intestinal motility; MOR; NAP; Pripheral opioid antagonist

Indexed keywords

CHARCOAL; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NALTREXAMINE DERIVATIVE; NALTREXONE; SODIUM CHLORIDE;

EID: 84863480944     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.05.075     Document Type: Article
Times cited : (22)

References (28)
  • 10
    • 80155191579 scopus 로고    scopus 로고
    • Wyeth Pharmaceuticals Inc. and Progenics Pharmaceuticals, Philadelphia, PA, and Tarrytown, NY
    • Relistor [package insert], Wyeth Pharmaceuticals Inc. and Progenics Pharmaceuticals, Philadelphia, PA, and Tarrytown, NY, 2009.
    • (2009) Relistor [Package Insert]
  • 12
    • 84872668232 scopus 로고    scopus 로고
    • US Food and Drug Administration Accessed Feb 6, 2012
    • US Food and Drug Administration. FDA approves Entereg to help restore bowel function following surgery. Available at: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2008/ucm116899.htm. Accessed Feb 6, 2012.
    • FDA Approves Entereg to Help Restore Bowel Function Following Surgery
  • 15
    • 84872664084 scopus 로고    scopus 로고
    • Adolor GlaxoSmithKline. Entereg (alvimopan). accessed Feb 6, 2012
    • Adolor GlaxoSmithKline. Entereg (alvimopan). www.entereg.com/ accessed Feb 6, 2012.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.